215 related articles for article (PubMed ID: 17602020)
1. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.
Gilmer TP; Dolder CR; Folsom DP; Mastin W; Jeste DV
Psychiatr Serv; 2007 Jul; 58(7):1007-10. PubMed ID: 17602020
[TBL] [Abstract][Full Text] [Related]
2. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
Velligan DI; Carroll C; Lage MJ; Fairman K
Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
[TBL] [Abstract][Full Text] [Related]
4. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
Marcus SC; Olfson M
Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
[TBL] [Abstract][Full Text] [Related]
6. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.
Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV
Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308
[TBL] [Abstract][Full Text] [Related]
7. Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program.
Tang Y; Horvitz-Lennon M; Gellad WF; Lave JR; Chang CH; Normand SL; Donohue JM
Psychiatr Serv; 2017 Jun; 68(6):579-586. PubMed ID: 28196460
[TBL] [Abstract][Full Text] [Related]
8. Polypharmacy as the initial second-generation antipsychotic treatment.
Lee B; Walker V
Psychiatr Serv; 2008 Jul; 59(7):717. PubMed ID: 18586985
[No Abstract] [Full Text] [Related]
9. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
10. National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States.
Patel C; Pilon D; Gupta D; Morrison L; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2022; 25(1):792-807. PubMed ID: 35635250
[TBL] [Abstract][Full Text] [Related]
11. How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs.
Valuck RJ; Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R;
Curr Med Res Opin; 2007 Oct; 23(10):2567-76. PubMed ID: 17848204
[TBL] [Abstract][Full Text] [Related]
12. High-cost use of second-generation antipsychotics under California's Medicaid program.
Stahl SM; Grady MM
Psychiatr Serv; 2006 Jan; 57(1):127-9. PubMed ID: 16399974
[TBL] [Abstract][Full Text] [Related]
13. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
[TBL] [Abstract][Full Text] [Related]
14. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
McCombs JS; Luo M; Johnstone BM; Shi L
Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
[TBL] [Abstract][Full Text] [Related]
15. Use patterns for antipsychotic medications in medicaid patients with schizophrenia.
McCombs JS; Nichol MB; Stimmel GL; Shi J; Smith RR
J Clin Psychiatry; 1999; 60 Suppl 19():5-11; discussion 12-3. PubMed ID: 10507275
[TBL] [Abstract][Full Text] [Related]
16. Use of Academic Detailing With Audit and Feedback to Improve Antipsychotic Pharmacotherapy.
Brunette MF; Cotes RO; de Nesnera A; McHugo G; Dzebisashvili N; Xie H; Bartels SJ
Psychiatr Serv; 2018 Sep; 69(9):1021-1028. PubMed ID: 29879874
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
[TBL] [Abstract][Full Text] [Related]
18. Long-term combination antipsychotic treatment in VA patients with schizophrenia.
Kreyenbuhl J; Valenstein M; McCarthy JF; Ganoczy D; Blow FC
Schizophr Res; 2006 May; 84(1):90-9. PubMed ID: 16631354
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia.
Gören JL; Meterko M; Williams S; Young GJ; Baker E; Chou CH; Kilbourne AM; Bauer MS
Psychiatr Serv; 2013 Jun; 64(6):527-33. PubMed ID: 23450334
[TBL] [Abstract][Full Text] [Related]
20. Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis.
Baandrup L; Sørensen J; Lublin H; Nordentoft M; Glenthoj B
Eur J Health Econ; 2012 Jun; 13(3):355-63. PubMed ID: 21452062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
